Study of Prostate Cancer in Black and White U.S. Veterans
NCT00007540 · Status: COMPLETED · Type: OBSERVATIONAL
Last updated 2009-01-21
Summary
Prostate cancer is diagnosed in approximately 334,500 men each year and accounts for nearly 41,800 deaths in the United States. Prostate cancer is the leading cancer affecting veterans and the second leading cancer among all Americans. The causes of prostate cancer and, particularly, the reasons for the unusually high incidence rates in African-Americans remain obscure. Dietary factors likely play a role in fatal cases, while hormones are also important in regulating prostate cancer growth. Dr. Charles Huggins recognized this effect in the 1940?s, with androgen deprivation remaining as the cornerstone of therapy for advanced disease. Despite the strong circumstantial evidence, neither epidemiologic studies nor basic sciences have produced clear insight into the etiologic role of hormones. However, recent observations regarding androgen receptor gene polymorphisms and their relation to endocrine expression and prostate cancer risk may be providing important clues as to how an etiologic role might be mediated at the molecular level. Thus, it is important to attempt to identify genetic markers of high-risk cancer patients for necessary screening and counseling efforts.
Conditions
- Prostate Cancer
- Prostatic Neoplasms
Sponsors & Collaborators
-
US Department of Veterans Affairs
lead FED
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-04-30
- Completion
- 2000-09-30
Countries
- United States
Study Locations
More Related Trials
-
Study of Rates of Prostate Cancer Diagnosis in Men of African Ancestry Using MRI and MRI Guided Biopsy
NCT05872503 ·Status: TERMINATED
-
Identification of Prostate Cancer Genes
NCT00342784 ·Status: COMPLETED
-
Optimizing Veteran-Centered Prostate Cancer Survivorship Care
NCT01900561 ·Status: COMPLETED ·Phase: NA
-
Detecting Recurrent Prostate Cancer With C-11 Choline Positron Emission Tomography: An Expanded Access Study
NCT02355054 ·Status: APPROVED_FOR_MARKETING
-
Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
NCT00924313 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer
NCT00082147 ·Status: COMPLETED ·Phase: NA
-
Prostate Cancer Detection Screening MRI Protocol
NCT04175730 ·Status: COMPLETED ·Phase: NA
-
Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue
NCT02594202 ·Status: RECRUITING
-
Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies
NCT04541030 ·Status: ACTIVE_NOT_RECRUITING
-
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
NCT04910425 ·Status: WITHDRAWN ·Phase: PHASE2
-
Flotufolastat F 18 PET in Men With Very Low PSA Recurrence
NCT06862856 ·Status: RECRUITING
-
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
NCT03181867 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer
NCT02624518 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Precision-Based Genomics in Prostate Cancer
NCT04706663 ·Status: RECRUITING
-
Study of Blood Samples From Older Patients at High Risk of Developing Prostate Cancer and From Healthy Male Participants
NCT00898274 ·Status: COMPLETED
-
Prostate Cancer Genetic Risk Evaluation and Screening Study
NCT05129605 ·Status: RECRUITING
-
PRISM: Patient Experiences With PET Imaging in Prostate Cancer
NCT06523777 ·Status: RECRUITING
-
Understanding of Genetics by Men at Risk for Prostate Cancer
NCT04550845 ·Status: RECRUITING ·Phase: NA
-
Frequency of Prostate-Specific Antigen Screening in African American Men in the San Francisco Area
NCT00702104 ·Status: COMPLETED
-
Predictive Value of Prostate-specific Antigen Isoform p2psa and Its Derivates in the Diagnosis of Prostate Cancer
NCT01672411 ·Status: COMPLETED
-
Exploiting Risk-Based Risk Stratification in Early Prostate Cancer to Discriminate Progressors From Non-Progressors
NCT04340245 ·Status: ACTIVE_NOT_RECRUITING
-
Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
NCT03444844 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Molecular Urine Tests for Prostate Cancer
NCT00581516 ·Status: COMPLETED
-
MRI/MRSI in Risk Assessment of Prostate Cancer Patients
NCT00582543 ·Status: COMPLETED ·Phase: NA
-
Genetic Analysis of Prostate Cancer to Identify Predictive Markers of Disease Relapse or Metastatic Evolution
NCT03421015 ·Status: COMPLETED